News

February’s Member of the Month- Quay Pharma

Further Investment at Quay Pharma

Pharmaceutical outsourcing specialist Quay Pharma is continuing its £3 million investment at its headquarters in Deeside with the creation of GMP manufacturing suites.

Established in 2001 by Professor Mike Rubinstein, Quay provides formulation, analytical development and clinical trials manufacturing for companies world-wide.  The company’s range of services includes early stage (pre-clinical) formulation development, novel drug delivery design, analytical R&D development, stability testing, and clinical trial manufacture and packing of new drug compounds.  Quay offers particular expertise in oral dosage form design and semi solids formulation and development, in particular new drugs that exhibit poor solubility and bio-availability.

The company moved to its purpose-designed headquarters in 2010 but retained its manufacturing operation on the Wirral.  The new GMP suites will not only bring all Quay’s services under one roof but will also increase its overall manufacturing capacity and enable it to make larger batches of product in order to continue support through phase 2b clinical trials for all non-sterile products.

The GMP facility will also support a number of Quay’s specialist areas where the company is experiencing increasing demand.  These include the development of orphan drugs and potent products.  In addition, one room will be equipped to allow the manufacture of products at very low humidity in order to meet another growing customer requirement for new innovative formulations.

Quay’s initial move to North Wales was supported by a £784,000 Single Investment Funding by the Welsh Assembly Government.  The company’s is funding this latest investment with backing from its bank, RBS.

We are very grateful for the support from the Welsh Assembly and RBS which was instrumental in facilitating our move to Deeside that has given us the capacity to grow our business,” comments Quay Pharma CEO Maireadh Pedersen.

“The establishment of the GMP suites here is the next logical step in our continued expansion and will further enhance the level of service and support that we can offer our clients.

Quay Pharma is MHRA licensed and FDA registered.  Its clients include both small and large pharmaceutical and biotechnology companies worldwide, with recent successes in a diverse number of territories including France, Germany, Switzerland, Israel and Japan.

 

 

ENQUIRIES:

Quay Pharma

Tel: +44 1244 837000

Fax: +44 1244 281 283

Email: enquiries@quaypharma.com

www.quaypharma.com